The aim of this study was to evaluate the joint count for @entity2681 in @entity1 with @entity571 ( @entity571 ) of the hands treated with 800 mg/day of orally administered chondroitin @entity597 plus @entity1623 , compared with that of @entity1 administered @entity1623 only. Twenty-four consecutive @entity1 (22 @entity1 and two @entity1 , mean age 53.0 +/- 6) suffering from symptomatic @entity571 and with radiographic characteristics of @entity571 were studied. The @entity1 were divided into two groups of 12 @entity1 each. The first group took @entity1623 500 mg/day only. The second group was treated with @entity12006 800 mg/day orally plus @entity1623 500 mg/day. Radiological hand examinations were performed at baseline and again after 12 and 24 months. In both groups, the joint count for @entity2681 showed a general tendency to increase over time. Progression of @entity2681 at 24 months was lower in @entity1 treated with 800 mg/day chondroitin @entity597 plus @entity1623 than in @entity1 taking @entity1623 only (p <0.05). Chondroitin @entity597 failed to stop the usual time-associated progression in the number of @entity2720 in @entity571 of the hands. It was, however, associated with a lower increase in the number of finger joints with @entity2681 detected after 2 years of radiological observation.

Chondroitin @entity597 in XXXX of the hands.

@entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men'] @entity571 :: ('MESH:D010003', 'Disease') :: ['EOA', 'erosive osteoarthritis', 'OA'] @entity2681 :: ('MESH:D014077', 'Disease') :: ['erosions'] @entity12006 :: ('MESH:D002809', 'Chemical') :: ['chondroitin sulfate'] @entity1623 :: ('MESH:D009288', 'Chemical') :: ['naproxen'] @entity2720 :: ('MESH:D007592', 'Disease') :: ['finger joints presenting erosions'] @entity597 :: ('CHEBI:16189', 'Chemical') :: ['sulfate']
@entity571 :: (MESH:D010003,Disease) :: ['erosive osteoarthritis']
